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Evidence that reduced lipoprotein lipase activity is not a primary
pathogenetic factor for hypertriglyceridemia in renal failure. The aim of
the study was to document postheparin plasma lipoprotein lipase (LPL)
and hepatic lipase activities and relate these to serum lipid, lipoprotein
and apolipoprotein concentrations in 85 patients with kidney function
ranging from normal to dialysis dependency. Strict selection criteria were
applied in order to exclude conditions other than renal failure which may
influence lipid metabolism. Stress was laid on minimizing proteinuria and
inflammatory activity. The changes in the lipoprotein pattern were numer-
ically strikingly modest compared to those previously reported. This
probably reflected the intention to elucidate the contribution of reduced
renal function as such to the dyslipoproteinemia of renal failure, a
condition often associated with confounding factors. Significant increases
in serum concentrations of triglycerides and apolipoprotein CIII were
already observed in moderate renal failure, whereas serum concentrations
of high density lipoprotein cholesterol and plasma LPL activities were
decreased only in severe renal failure. Plasma LPL activities were not
significantly reduced in hemodialysis patients (probably due to anticoag-
ulation with low molecular weight heparin), but serum concentrations of
triglycerides and apolipoprotein CIII were significantly increased. A
multiple regression analysis, taking glomerular filtration rate, LPL and
apolipoprotein CIII into account, showed that both plasma LPL activity
and serum apolipoprotein CIII concentration independently predicted
serum triglyceride concentration. However, serum apolipoprotein CIII
concentration was a much stronger predictor than plasma LPL activity.
Thus, a decrease in LPL activity does not seem to be a prerequisite for the
hypertriglyceridemia of uremia, but it probably accentuates this condition.
The basal disturbance in the lipoprotein metabolism in renal failure might
be poor substrate characterictics of triglyceride-rich lipoproteins for LPL,
possibly due to alterations in apolipoprotein composition. Plasma hepatic
lipase activities were independent of renal function.
Hypertriglyceridemia in patients on hemodialysis was first
reported by Bagdade, Porte and Bierman in 1968 [1]. Since then
this phenomenon has been frequently observed, generally in
combination with low concentration of high density lipoprotein
(HDL) cholesterol [2—4]. Low enzyme activity of lipoprotein
lipase (LPL) [5—71 has been assumed to play an important
pathogenetic role as the lipolytic reaction is the rate-limiting step
in the catabolism of triglyceride-rich lipoproteins. Low activity of
hepatic lipase (HL) has also been reported [5, 6, 8]. Furthermore,
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the apolipoprotein composition of the lipoprotein particles of
uremic patients has been shown to be disturbed, which probably
influences their metabolic pathways. Generally, an increase in
apolipoprotein CIII contents of very low density lipoprotein
(VLDL) and HDL as well as a decrease in apolipoprotein AL
contents of HDL have been found [9, 10].
The lipid metabolism of patients on hemodialysis has been
extensively studied but only a few studies involved patients with
less advanced renal failure [11—14]. In general, these studies have
shown moderate hypertriglyceridemia relatively early in renal
failure. Changes in the apolipoprotein composition of the lipopro-
tein particles seem to occur even earlier [11]. On the other hand,
lipase activities have not been studied in adult patients with
different degrees of renal failure. The main objective of the
present investigation was to study postheparin plasma lipase
activities and their relation to serum concentrations of lipids,
lipoproteins and apolipoproteins in patients with a wide range of
glomerular filtration rates (GFR). To investigate the influence of
GFR, confounding factors such as proteinuria and inflammatory
activity were excluded as strictly as possible.
Methods
Patients
Patients with renal function ranging from normal to dialysis
dependency were recruited from the ambulatory clinic of the
Department of Nephrology at the University Hospital, Lund, and
from Park Dialysis, Lund. All renal diagnoses were allowed as far
as they were compatible with the selection criteria (see below).
The hemodialysis patients were treated four to five hours three
times a week with cuprophane dialyzers. All were on bicarbonate
dialysis, receiving low molecular weight heparin (Fragmin, Kabi
Pharmacia, Uppsala, Sweden) for anticoagulation. All received
adequate dialysis as judged by routine clinical and laboratory
parameters.
Roughly one thousand patient records were scanned in search
for suitable study participants. Patients were asked to participate
if there were no signs of the following conditions: diabetes,
endocrine disease, obesity, liver disease, cancer, active inflamma-
tory disease, recent infection, abnormalities of fluid balance,
moderate-severe proteinuria and treatment with steroids, ciclo-
sporin or lipid-lowering drugs.
If not in the habitual condition on the planned test occasion, the
patient was excluded from participation in the study or blood
sampling was postponed.
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Table 1. Characteristics of the glomerular filtration rate (GFR) groups
Group 1(N = 24)
Group 2(N = 26)
Group 3
(N = 22)
Group 4
(N = 13)
GFR mt/mm 85 12 51 9 18 7 —
Age years 49 11 53 16 59 17 61 16
Female/male 11/13 10/16 6/16 6/7
Duration of dialysis months — — — 24 (7-154)
Body mass index kg/m2 24.7 3.6 24.2 2.5 25.6 4.0 22.2 2.9
Plasma albumin g/liter 39 3 38 4 37 4 39 3
Urine albumin mg/liter 13 (4—395) 25 (4—385) 165 (9—500) 0 (0—482)
13-blockers and/or diuretics % 4 19 41 8
Distribution is expressed as mean SD or median (range).
Blood was collected from 102 patients. Of these 17 were
excluded from statistical analysis, in most cases because of exces-
sive proteinuria and/or signs of moderate-severe inflammatory
activity in the plasma protein pattern. Most of the excluded
patients had low GFR.
Urine albumin concentration up to 0.5 g/liter and a mild
inflammatory activity in the plasma protein pattern were allowed.
The following criteria were applied regarding plasma protein
concentrations (upper reference limit in parenthesis): c-1-anti-
trypsin  1.70 mg/liter (1.70 mg/liter), orosomucoid 1.20
mg/liter in groups 1 and 2 (see below) and 1.50 mg/liter in
groups 3 and 4 (1.05 mg/liter), haptoglobin s 2.50 mg/liter (1.80
mg/liter) and C-reactive protein 10 mg/liter (5 mg/liter). The
upper reference limit applied for other inclusion variables,
The patients were divided into groups according to GFR. The
reference group (group 1) consisted of patients with essentially
normal renal function (GFR = 67 to 107 mI/mm), group 2 of
patients with moderate renal failure (GFR = 36 to 63 mI/mm),
group 3 of predialytic patients with advanced renal failure (GFR
= 6 to 32 mi/mm) and group 4 of patients on hemodialysis.
In GFR group I the diagnoses were: chronic glomerulonephri-
tis (9), chronic interstitial nephritis (7), nephrosclerosis (6),
polycystic kidney disease (1), nephropathy of unknown origin (1).
In the GFR group 2 the diagnoses were: chronic glomerulone-
phritis (5), chronic interstitial nephritis (10), nephrosclerosis (6),
polycystic kidney disease (3), nephropathy of unknown origin (2).
Diagnoses in the GFR group 3 were: chronic glomerulonephritis
(4), chronic interstitial nephritis (4), nephrosclerosis (7), polycys-
tic kidney disease (4), hereditary nephritis (2), nephropathy of
unknown origin (1). In GFR group 4 the diagnoses were: chronic
giomerulonephritis (3), chronic interstitial nephritis (3), polycystic
kidney disease (4), hereditary nephritis (2), nephropathy of un-
known origin (1). Other characteristics of the groups are shown in
Table 1.
Procedure
The tests were performed after an overnight fast.
1. Urine sampling. A sample of urine, voided at the ambulatory
clinic, was collected for analysis of albumin concentration.
2. Blood sampling. Blood was collected via an indwelling
catheter for analysis of the following:
(a) Lipid, lipoprotein and apolipoprotein variables were: serum
concentrations of total cholesterol, HDL cholesterol, triglycer-
ides, apolipoprotein AT, apolipoprotein B and apolipoprotein
CIII.
(b) Inclusion variables were: serum gamma glutamyltrans-
ferase, aspartic acid aminotransferase and alanine aminotransfer-
ase activities, serum thyroid stimulating hormone concentration,
blood glucose concentration and plasma protein analysis (electro-
phoresis, concentrations of albumin, alpha-i -antitrypsin, oroso-
mucoid, haptoglobin, C-reactive protein, immunoglobulins G, A,
and M).
3. Heparin test. Heparin (LOvens, Ballerup, Denmark) was
injected intravenously at a dose of 50 lU/kg body wt. After fifteen
minutes blood was collected in an EDTA tube, which was
immediately chilled on ice and centrifuged within an hour. Plasma
was stored frozen at —70°C to allow analysis of LPL and HL
activities in the same series.
4. GFR test. GFR was measured by plasma clearance of iohexol
[15]. Five ml of iohexol [Omnipaque (300 mg iodine/ml), Ny-
corned, Herlev, Danmark] was administered intravenously. A
blood sample was collected after 4 to 24 hours for iohexol analysis,
the time interval depending on the estimated GFR [16]. The
hemodialysis patients were excluded from this procedure.
Analytical methods
Serum lipids were analyzed with enzymatic methods (Boehring-
er-Mannheim, Mannheim, Germany). Serum HDL cholesterol
concentrations were analyzed after precipitation of LDL and
VLDL cholesterol with dextran sulphate and magnesium chloride
[17]. Serum LDL cholesterol concentrations were calculated by
the Friedewald formula [18].
Serum concentrations of apolipoprotein Al and apolipoprotein
B were analyzed by immunoturbidimetry with reagents from
Roche (Basel, Switzerland). Serum concentrations of apolipopro-
tein CIII were measured by noncompetitive, enzyme-linked im-
munosorbent assay as described by Parsy et al [19]; the analyses
were performed at Institut Pasteur, Lille, France.
Concentrations of plasma proteins and urine albumin were
analyzed by immunoturbidimetry (Roche).
Postheparin plasma lipase activities were measured with direct
and selective methods, using sonicated [3H]-trioleoylglycerol
emulsions, stabilized by phosphatidyl choline, as substrates [20].
As LPL, but not HL, rapidly hydrolyzes a substrate emulsion to
which albumin has been added after sonication, specific measure-
ments were achieved at pH 8.0, 0.15 M NaCI, and in the presence
of serum. HL activities were selectively determined, using a
substrate sonicated in the presence of albumin, by assay at pH 9.0
and 0.5 M NaCl. The assays were highly specific, as evidenced by
the almost total lack of activity of purified HL in the assay system
for LPL and vice versa. The intraassay variation of the lipase
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Table 2. Serum concentrations of lipids, lipoproteins and apolipoproteins as well as postheparin plasma lipase activities of the glomerular filtration
rate groups
Group 1 Group 2 Group 3 Group 4
Serum triglycerides mmol/liter 0.86 0.48 1.16 0.55' 1.36 0.53a 1.26 Q53a
Serum cholesterol mmol/liter 5.1 1.0 5.6 1.1 5.7 1.2 6.1 1.2
Serum HDL cholesterol mmol/liter 1.34 0.37 1.32 0.39 1.15 0.30a 1.24 0.32
Serum LDL cholesterol mmol/liter 3.4 0.9 3.8 1.1 3.9 1.0 4.3 1.la
Serum apolipoprotein AT glliter 1.19 0.16 1.28 0.22 1.19 0.24 1.33 0.22
Serum apolipoprotein B glliter 1.06 0.31 1.14 0.30 1.12 0.27 1.12 0.28
Serum apolipoprotein CIII g/liter 0.014 0.005 0.019 0.007a 0.021 0.OlOa 0.028 0.Olla
Plasma lipoprotein lipase mU/mi 81 35 79 39 55 16 70 35
Plasma hepatic lipase mU/mi 291 130 322 113 279 111 296 139
Data are expressedas mean so.
a P < 0.05, compared with group 1
Table 3. Significant correlations between variables (serum lipid, lipoprotein and apolipoprotein concentrations, postheparin plasma lipase activities
and glomerular fibration rate), evaluated by univariate regression analysis
Variable 1 Variable 2 r P <
Glomerular filtration rate Serum triglycerides —0.31 0.01
Glomerular filtration rate Serum HDL cholesterol 0.26 0.05
Glomerular filtration rate Serum apolipoprotein CIII —0.29 0.05
Glomerular filtration rate Lipoprotein lipase activity 0.32 0.01
Lipoprotein lipase activity Serum triglycerides —0.47 0.0001
Lipoprotein lipase activity Serum HDL cholesterol 0.46 0.0001
Lipoprotein lipase activity Serum apolipoprotein Al 0.23 0.05
Lipoprotein lipase activity Serum apolipoprotein CIII —0.36 0.01
Hepatic lipase activity Serum triglycerides 0.24 0.05
Hepatic lipase activity Serum HDL cholesterol —0.26 0.05
Serum apolipoprotein CIII Serum triglycerides 0.75 0.0001
Serum apolipoprotein CIII Serum HDL cholesterol —0.28 0.05
activity analyses was <4%. One mU of lipase activity represents
the release of 1 nmol of fatty acid per minute.
GFR was estimated with a single sample method with iohexol as
a marker [15]. The plasma concentration of iohexol was analyzed
by high performance liquid chromatography. GFR was expressed
as ml/min/1.73 m2 body surface.
Statistical methods
Differences between GFR groups were estimated with the
Mann-Whitney U-test and differences in variance between the
groups with the Kruskal-Wallis test. Correlations between vari-
ables were assessed by simple regression analysis. To investigate
the interrelationship between several variables, multiple regres-
sion analysis was performed. P < 0.05 was considered significant.
Results
Serum lipid, lipoprotein and apolipoprotein concentrations as
well as postheparin plasma lipase activities of the GFR groups are
accounted for in Table 2. There and in the text, comparisons are
made with GFR group 1, if not otherwise stated. The main
findings in predialytic patients were an unchanged activity of
plasma LPL in moderate renal failure (GFR group 2) and a
significantly decreased plasma LPL activity in severe renal failure
(GFR group 3). On the other hand, there were no differences
between the GFR groups in plasma HL activities, neither in men
nor in women. A significant increase in serum triglyceride con-
centration occurred already in moderate renal failure (GFR
group 2) and was more pronounced in GFR group 3. A significant
decrease in serum HDL cholesterol concentration was found only
in GFR group 3.
In hemodialysis patients (GFR group 4), plasma LPL activity
was numerically in between but statistically not significantly
different from those in GFR groups 1 and 3. Plasma HL activity
was unchanged. There were significant increases in serum con-
centrations of triglycerides, total cholesterol and LDL cholesterol.
There were no significant differences between the groups
regarding serum concentrations of apolipoprotein Al and apoli-
poprotein B, but those of apolipoprotein CIII were significantly
increased in GFR groups 2, 3 and 4.
According to the Kruskal-Wallis test, the variance between the
groups was significantly different for serum concentrations of
triglycerides (P < 0.01) and apolipoprotein CIII (P < 0.0001) as
well as plasma LPL activity (P < 0.05).
The patients in GFR group 4 were excluded from regression
analyses due to the special characteristics of those patients.
Statistically significant correlations are shown in Table 3, the
relationship between serum triglyceride concentrations and
plasma LPL activities is shown in Figure 1 and the relationship
between serum triglyceride concentrations and serum apolipopro-
tein CIII concentrations is shown in Figure 2. Multiple regression
analysis, including GFR, plasma LPL activity and serum apoli-
poprotein CIII concentration, showed that both plasma LPL
activity (r = —0.22, P < 0.05) and apolipoprotein CIII concen-
tration (r = 0.66, P < 0.0001) independently predicted triglyceride
concentration, whereas GFR did not. Together, these factors
explain 62% of the variation in serum triglyceride concentrations.
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Fig. 1. Postheparin plasma lipoprotein lipase activities (LPL, mU/mi) plot-
ted against serum triglyceride concentrations (TG, mmoi/iiter). The linear
regression coefficient was —0.47.
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Fig. 2. Serum apolipoprotein CIII concentrations (Apo CIII, glliter) plotted
against serum triglyceride concentrations (TG, mmol/liter). The linear
regression coefficient was 0.75.
A multiple regression analysis, including the same factors, showed
that only plasma LPL activity correlated independently with
serum HDL concentrations (r = 0.39, P < 0.01).
Discussion
The purpose of the present study was to document postheparin
plasma lipase activities in patients with different degrees of renal
failure and relate these to serum lipid, lipoprotein and apoli-
poprotein concentrations, in a patient material as free as possible
from confounding factors such as proteinuria and inflammatory
activity. Postheparin plasma LPL activities were found to be
significantly decreased in predialytic patients with GFR below 30
ml/min, whereas HL activities remained unchanged throughout
the whole spectrum of renal function. Serum concentrations of
triglycerides and apolipoprotein CIII were significantly increased
already in moderate renal failure. Figure 3 illustrates the close
relation between, on one hand, serum concentrations of triglyc-
erides and apolipoprotein CIII and, on the other hand, between
serum concentrations of HDL cholesterol and plasma LPL activ-
1 23 1 23
Group Group
Fig. 3. Serum concentrations of triglycerides (TG), high density lipoprotein
cholesterol (HDL CHOL) and apolipoprotein CIII (APO CIII) as well as
postheparin plasma lipoprotein lipase activities (LPL) as percentages of the
reference group levels. Group 1 (reference group) comprised those with
essentially normal renal function; group 2 had moderate renal failure, and
group 3 advanced renal failure (predialytic).
ities in predialytic patients. The changes in the serum lipoprotein
profile observed were statistically significant but numerically
strikingly discreet.
Stress was laid on excluding patients with factors, other than
renal insufficiency, which might influence lipid metabolism. In
particular, pains were taken to keep urinary protein excretion at
low levels and to avoid active inflammatory states. However, we
did not succeed to match the groups perfectly (Table 1). Medica-
tion with a-blockers and diuretics were by necessity allowed. In
GFR group 3, almost half of the patients were taking either or
both types of medication, but lipids and lipases were almost
identical in these patients as compared with the remainder of
GFR group 3. The patients with advanced renal failure were
slightly older than the reference group, but in all groups, the
patients were generally over 40 years of age, after which there are
negligible increases in plasma lipid and lipoprotein concentrations
in the population in Southern Sweden [21]. Therefore, we find it
unlikely that these discrepancies between the groups influenced
the statistical analysis of the findings. Other factors influencing
lipid metabolism were strictly excluded, which is probably the
reason why the changes in the serum lipoprotein profile at all
stages of renal insufficiency were strikingly modest.
Hyperlipidemia is an integral part of the nephrotic syndrom
[22]. As changes in lipid concentrations have been found to
correlate with urinary albumin excretion [23], even non-nephrotic
proteinuria would be expected to influence lipid metabolism. In a
patient material, proteinuria can hardly be totally eliminated, but
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in the present patient material, the urinaly albumin excretion was
indeed very low. It has been shown that mediators of inflamma-
tion (the cytokines) inhibit LPL activity [24], findings which offer
an explanation of the hypertriglyceridemia in, for example, sepsis.
Therefore, patients were excluded from the study if there was any
clinical indication of inflammatory activity, and excluded from
statistical analysis if there were more than mild increases in
concentrations of acute phase reactants, which reflect an increase
in cytokine production. Inflammatory states were more common
in patients with severe reduction in GFR and, in many cases, not
suspected on clinical grounds. Thus, there is a reason to believe
that the hypertriglyceridemia, commonly reported in renal failure,
is partly related to (subclinical) inflammation.
Plasma LPL activities in patients on hemodialysis were not
significantly different from those of patients with normal kidney
function. In the light of the findings in other studies [5—7, 25] this
was surprising, but can probably be explained by the treatment
with low molecular weight heparin. It has been suggested that
long-term treatment with unfractionated heparin gradually de-
pletes the tissue stores of LPL [26] and the superior lipid profile,
reported to be associated with treatment with low molecular
weight heparin [27, 28], has been assumed to depend on the
absence of the influence of unfractionated heparin. We have
recently demonstrated that the reduced postheparin plasma LPL
activity of hemodialysis patients improved significantly when low
molecular weight heparin was substituted for unfractionated
heparin [29]. Therefore, only patients treated with low molecular
weight heparin were included in the study. Thus, this group of
dialysis patients was special in two aspects: the above-mentioned
strict exclusion criteria were applied and the LPL-depleting effect
of heparin was minimized. The result was a group of dialysis
patients with near normal plasma LPL activity, which probably
explains the absence of a decrease in serum HDL cholesterol
concentration (Table 2). In spite of essentially normal plasma
LPL activity, the dialysis patients were clearly hypertriglyceride-
mic. We have recently found that VLDL particles of hemodialysis
patients function poorly as substrate for bovine LPL (unpublished
results). Thus, the increase in serum triglyceride concentration in
the absence of a decrease in LPL activity might be explained by an
inferior substrate function of triglyceride-rich lipoproteins. A
significantly increased serum apolipoprotein CIII concentration
was found in the hemodialysis patients. An increase in the
proportion of apolipoprotein CIII at the expense of apolipopro-
tein E in uremic VLDL may affect both the lipolytic degradation
of VLDL and the subsequent uptake of VLDL and LDL via
lipoprotein receptors, offering a tentative explanation of the
moderately elevated serum concentrations of total and LDL
cholesterol in the present study, which is otherwise a rather
unusual finding in hemodialysis patients.
There are many reports of decreased postheparin plasma LPL
activities in hemodialysis patients [5—71. Less is known about
plasma LPL activities at earlier stages of renal failure. A small
study in pediatric patients showed a decrease in plasma LPL
activities in severe renal failure, but no correlation between the
lipase activities and lipid concentrations [30]. In the present study,
plasma LPL activity declined relatively late in renal failure, later
than the rise in serum triglyceride concentration. Plasma LPL
activity independently predicted serum triglyceride concentration.
However, the serum apolipoprotein CIII concentration was a
much stronger predictor for the degree of hypertriglyceridemia.
Again, an inferior substrate function of triglyceride-rich lipopro-
teins might explain the relatively early rise in serum triglyceride
concentration, which indeed coincided with the increase in serum
apolipoprotein CIII concentration (Fig. 3). The inverse correla-
tion between plasma LPL activities and serum apolipoprotein
CIII concentrations is of interest in this context. It can, at least
partially, be explained by the accumulation of apolipoprotein
CIlI-rich lipoproteins due to reduced LPL activity. However, it is
also possible that increased apolipoprotein CIII content of the
lipoprotein particles adversely influences their substrate charac-
teristics for LPL, thus precipitating hypertriglyceridemia.
It should be borne in mind that the present study aimed at
investigating the effect of GFR on lipoproteins and lipases. The
patient selection reflects this purpose and does not represent the
average patient material with renal insufficiency. Such patients
often suffer from other ailments, known to influence LPL activity,
and it is likely that reduced LPL activity is of greater importance
in an unselected patient material. However, it can be concluded
that with respect to reduced renal function, LPL activity does not
seem to be a primary pathogenetic factor for hypertriglyceri-
demia.
Plasma ilL activity was unchanged throughout the spectrum of
renal function and in hemodialysis patients. This is in accord with
our previous findings in a group of less strictly selected hemodi-
alysis patients [25] and the findings of Joven et al [31], but in
contrast to the findings of several investigators [5, 6, 8].
In conclusion, we suggest that alterations in the composition of
triglyceride-rich lipoproteins, notably increased contents of apo-
lipoprotein CIII, is the earliest sign of dyslipoproteinemia in
patients with declining renal function. The altered characteristics
of lipoproteins lead to impaired clearance via lipolytic and
receptor-mediated pathways. With progressing renal function
impairment, the activity of LPL falls, further accentuating the
hypertriglyceridemia. In patients on chronic hemodialysis, re-
peated injections of unfractionated heparin may further interfere
with the LPL system and add to the elimination defect. At any
stage in the development of renal failure, concomitant inflamma-
tion may aggravate the dyslipoproteinemia by depressing LPL
activity and, possibly, HL activity.
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